100,000 Genomes Project

100,000 Genomes Project
Name	100,000 Genomes Project
Founder	Theresa May; Jeremy Hunt
Established	2012
Dissolved	2018
Headquarters	London

100,000 Genomes Project The 100,000 Genomes Project was a United Kingdom initiative to sequence large numbers of human genomes to advance diagnosis and treatment of rare diseases and cancers. Launched under the aegis of National Health Service leadership and supported by UK Research and Innovation, it brought together clinical institutions such as Genomics England, academic centres including University of Cambridge and University College London, industry partners like Illumina and funders including Wellcome Trust and Department of Health and Social Care. The programme aimed to integrate genomic data with clinical records from NHS patients and to catalyse translational research across Cambridge Biomedical Campus, Great Ormond Street Hospital, and regional genomic medicine centres.

Background and Objectives

The initiative was announced by David Cameron and developed during the premiership of Theresa May with health secretaries including Jeremy Hunt involved in oversight, responding to policy drives from Chief Medical Officers and advisory bodies such as NHS England and Health Education England. Objectives targeted rare inherited disorders, common cancers, and infectious disease genomics, aligning with priorities from Medical Research Council and National Institute for Health and Care Excellence. The project intended to create a secure research database, support diagnostics at centres like Great Ormond Street Hospital and Royal Marsden Hospital, and stimulate biotech growth in clusters such as Cambridge and Oxford.

Organization and Governance

Governance combined public bodies and private partners: Genomics England as the delivery body interfaced with NHS England, regulators such as Medicines and Healthcare products Regulatory Agency and ethics oversight from Health Research Authority. Operational collaborations involved academic institutions including Imperial College London and University of Oxford, research funders such as Wellcome Trust and industry collaborators like Illumina and Life Technologies. Data access committees included representation from patient groups, clinical leads from specialist centres such as Great Ormond Street Hospital for Children NHS Foundation Trust, and legal advisors connected to Ministry of Justice (United Kingdom). Strategic alignment drew on national strategies from Department of Health and Social Care and international dialogues with organisations such as European Molecular Biology Laboratory.

Methodology and Data Collection

Participant recruitment occurred via NHS trusts including Guy's and St Thomas' NHS Foundation Trust and specialised centres like Royal Marsden Hospital with consent processes overseen by the Health Research Authority and patient advocacy organisations including Genetic Alliance UK. Samples were collected, processed, and sequenced using platforms from companies such as Illumina and analysed with pipelines developed in collaboration with university groups at Wellcome Sanger Institute and University College London. Clinical phenotypes were curated from electronic health records in hospitals such as Addenbrooke's Hospital and linked with biobanks including UK Biobank standards for metadata. Bioinformatics workflows incorporated reference resources like 1000 Genomes Project and annotation from Ensembl and ClinVar, while secure data access models referenced frameworks promoted by NHS Digital and advisory inputs from Information Commissioner's Office.

Findings and Scientific Impact

The programme reported diagnostic yields influencing practice at specialist centres including Great Ormond Street Hospital and Royal Marsden Hospital and contributed variant curation to repositories used by American College of Medical Genetics and Genomics guideline development. Discoveries informed mechanistic studies at institutions including Wellcome Sanger Institute and Francis Crick Institute and influenced translational pipelines in biotech firms clustered around Cambridge Biomedical Campus and Oxford Science Park. Outcomes were cited in collaborations with organisations such as Cancer Research UK and in policy discussions involving National Institute for Health and Care Excellence about precision medicine implementation. The dataset underpinned publications involving consortia with partners at University of Cambridge, Imperial College London, and University College London and enabled downstream analyses comparing population variation from projects like UK10K and 1000 Genomes Project.

Ethical, Legal, and Social Issues

Ethical frameworks were developed in consultation with the Health Research Authority, patient groups like Genetic Alliance UK, and legal stakeholders from Department of Health and Social Care and Ministry of Justice (United Kingdom). Core debates involved consent models used by Genomics England, data governance aligned to standards from Information Commissioner's Office, return of incidental findings discussed with clinical genetics teams at Great Ormond Street Hospital, and commercial access arrangements scrutinised by members of Parliament of the United Kingdom. International comparisons were drawn with governance in projects led by National Institutes of Health and programmes influenced by guidance from World Health Organization.

Legacy and Follow-up Programs

Post-completion, infrastructure and policy outputs evolved into national genomic medicine services integrated within NHS England and informed strategy at agencies such as UK Research and Innovation and National Institute for Health and Care Research. Successor initiatives and regional genomic medicine hubs involved partners including Genomics England, academic centres like University of Cambridge and Imperial College London, and industry collaborators such as Illumina. The project legacy influenced training programmes through Health Education England and spurred commercial and academic spinouts in clusters like Oxford and Cambridge, while datasets continued to support research in consortia connected to Cancer Research UK, Wellcome Trust, and international collaborations with European Molecular Biology Laboratory.

Category:Genomics projects